Disclosures for "Chronic Kidney Disease and Risk of Intracerebral Hemorrhage: The Role of Hypertension as a Mediator"
-
Mr. Vanent has nothing to disclose.
-
Dr. Rivier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pyxis Partners.
-
Charles Matouk has nothing to disclose.
-
Dr. Levitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Levitt has received personal compensation in the range of $0-$499 for serving as a Consultant for Metis Innovative. Dr. Levitt has received personal compensation in the range of $0-$499 for serving as a Consultant for Aeaean Consulting, LLC. Dr. Levitt has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of NeuroInterventional Surgery. Dr. Levitt has received stock or an ownership interest from Proprio. Dr. Levitt has received stock or an ownership interest from Synchron. Dr. Levitt has received stock or an ownership interest from Cerebrotech. Dr. Levitt has received stock or an ownership interest from Hyperion Surgical. The institution of Dr. Levitt has received research support from Medtronic. The institution of Dr. Levitt has received research support from Stryker. Dr. Levitt has received publishing royalties from a publication relating to health care.
-
Dr. Leslie-Mazwi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for World Care Clinical. Dr. Leslie-Mazwi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Phillips Health Care. Dr. Leslie-Mazwi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Leslie-Mazwi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll.
-
Thomas Gill has nothing to disclose.
-
Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.